WO2000078361A3 - Methods of imaging and targeting tumor vasculature - Google Patents

Methods of imaging and targeting tumor vasculature Download PDF

Info

Publication number
WO2000078361A3
WO2000078361A3 PCT/US2000/015732 US0015732W WO0078361A3 WO 2000078361 A3 WO2000078361 A3 WO 2000078361A3 US 0015732 W US0015732 W US 0015732W WO 0078361 A3 WO0078361 A3 WO 0078361A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor vasculature
imaging
methods
targeting tumor
targeting
Prior art date
Application number
PCT/US2000/015732
Other languages
French (fr)
Other versions
WO2000078361A2 (en
Inventor
Stanley J Wiegand
Original Assignee
Regeneron Pharma
Stanley J Wiegand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Stanley J Wiegand filed Critical Regeneron Pharma
Priority to AU54722/00A priority Critical patent/AU5472200A/en
Priority to EP00939669A priority patent/EP1185307A2/en
Priority to IL14709700A priority patent/IL147097A0/en
Priority to JP2001504422A priority patent/JP2003502391A/en
Priority to CA002377188A priority patent/CA2377188A1/en
Publication of WO2000078361A2 publication Critical patent/WO2000078361A2/en
Publication of WO2000078361A3 publication Critical patent/WO2000078361A3/en
Priority to HK02104978.6A priority patent/HK1043314A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

Methods for imaging and targeting tumor vasculature are provided. Specifically, the methods for imaging and targeting tumor vasculature relate to using angiopoietin-2 (Ang-2) to image developing tumor vasculature and to target therapeutic agents to developing tumor vasculature. Kits for imaging and targeting tumor vasculature are also provided.
PCT/US2000/015732 1999-06-17 2000-06-08 Methods of imaging and targeting tumor vasculature WO2000078361A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU54722/00A AU5472200A (en) 1999-06-17 2000-06-08 Methods of imaging and targeting tumor vasculature
EP00939669A EP1185307A2 (en) 1999-06-17 2000-06-08 Methods of imaging and targeting tumor vasculature
IL14709700A IL147097A0 (en) 1999-06-17 2000-06-08 Methods of imaging and targeting tumor vasculature
JP2001504422A JP2003502391A (en) 1999-06-17 2000-06-08 Methods of imaging and targeting tumor vasculature
CA002377188A CA2377188A1 (en) 1999-06-17 2000-06-08 Methods of imaging and targeting tumor vasculature
HK02104978.6A HK1043314A1 (en) 1999-06-17 2002-07-03 Methods of imaging and targeting tumor vasculature

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13964299P 1999-06-17 1999-06-17
US60/139,642 1999-06-17

Publications (2)

Publication Number Publication Date
WO2000078361A2 WO2000078361A2 (en) 2000-12-28
WO2000078361A3 true WO2000078361A3 (en) 2001-08-09

Family

ID=22487626

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015732 WO2000078361A2 (en) 1999-06-17 2000-06-08 Methods of imaging and targeting tumor vasculature

Country Status (7)

Country Link
EP (1) EP1185307A2 (en)
JP (1) JP2003502391A (en)
AU (1) AU5472200A (en)
CA (1) CA2377188A1 (en)
HK (1) HK1043314A1 (en)
IL (1) IL147097A0 (en)
WO (1) WO2000078361A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118585A1 (en) 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
US20030165263A1 (en) 2002-02-19 2003-09-04 Hamer Michael J. Histological assessment
AU2005249540B2 (en) 2004-06-02 2009-02-19 Sidney Kimmel Cancer Center Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
JP5139058B2 (en) 2004-06-02 2013-02-06 シドニー キンメル キャンサー センター Vascular targets for detection, imaging and treatment of neoplasia or neovasculature

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040947A2 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO2000018439A2 (en) * 1998-09-29 2000-04-06 Schering Aktiengesellschaft Use of neoangiogenesis markers for diagnosing and treating tumours by therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040947A2 (en) * 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules
WO2000018439A2 (en) * 1998-09-29 2000-04-06 Schering Aktiengesellschaft Use of neoangiogenesis markers for diagnosing and treating tumours by therapy

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
ASAHARA T ET AL: "TIE2 RECEPTOR LIGANDS, ANGIOPOIETIN-1 AND ANGIOPOIETIN-2, MODULATE VEGF-INDUCED POSTNATAL NEOVASCULARIZATION", CIRCULATION RESEARCH,US,GRUNE AND STRATTON, BALTIMORE, vol. 83, no. 3, 1998, pages 233 - 240, XP000907290, ISSN: 0009-7330 *
BERNS A: "Mouse models for cancer at center stage - AACR special meeting: Cancer Biology and the Mutant Mouse: New Methods, New Models, New Insights, Keystone Colorado, USA, 31 January - 5 February 1999", TRENDS IN GENETICS, vol. 15, no. 5, 1 May 1999 (1999-05-01), ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, pages 177, XP004167929, ISSN: 0168-9525 *
CHAN A S Y ET AL: "Angiopoietin-2 and VEGF co-express in the accelerated phase of angiogenesis during anaplastic progression of gliomas.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), & 90th Annual Meeting of the American Association for Cancer Research; Philadelphia, Pennsylvania, USA; April 10-14, 1999, pages 414, ABSTRACT NO. 2738, XP002158783, ISSN: 0197-016X *
DING H ET AL: "Expression and hypoxic regulation of angiopoietins and its receptors in human astrocytoma cell lines and tumor specimens.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), & 90th Annual Meeting of the American Association for Cancer Research; Philadelphia, Pennsylvania, USA; April 10-14, 1999, pages 556, ABSTRACT NO. 3664, XP002158782, ISSN: 0197-016X *
FUJIKAWA K ET AL: "Expression of angiopoietin 1, angiopoietin 2, tie 1 and tie 2 receptors in breast cancer.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), & 40th Annual Meeting of the American Society of Hematology; Miami Beach, Florida, USA; December 4-8, 1998, pages 174A, abstract no. 703, XP000979182, ISSN: 0006-4971 *
HOLASH J ET AL: "New model of tumor angiogenesis: Dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.", ONCOGENE, vol. 18, no. 38, pages 5356 - 5362, XP000979138, ISSN: 0950-9232 *
HOLASH J ET AL: "Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.", SCIENCE (WASHINGTON D C), vol. 284, no. 5422, 18 June 1999 (1999-06-18), pages 1994 - 1998, XP002158988, ISSN: 0036-8075 *
IJLAND S A J ET AL: "Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines.", MELANOMA RESEARCH, vol. 9, no. 5, October 1999 (1999-10-01), pages 445 - 450, XP000979142, ISSN: 0960-8931 *
LAUREN JUHA ET AL: "Is angiopoietin-2 necessary for the initiation of tumor angiogenesis?", AMERICAN JOURNAL OF PATHOLOGY, vol. 153, no. 5, November 1998 (1998-11-01), pages 1333 - 1339, XP000979136, ISSN: 0002-9440 *
LIN P ET AL: "ANTIANGIOGENIC GENE THERAPY TARGETING THE ENDOTHELIUM-SPECIFIC RECEPTOR TYROSINE KINASE TIE2", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 95, July 1998 (1998-07-01), pages 8829 - 8834, XP000857192, ISSN: 0027-8424 *
MOLEMA GRIETJE ET AL: "The use of bispecific antibodies in tumor cell and tumor vasculature directed immunotherapy.", JOURNAL OF CONTROLLED RELEASE, vol. 64, no. 1-3, 14 February 2000 (2000-02-14), pages 229 - 239, XP004185107, ISSN: 0168-3659 *
PROCEEDINGS OF THE FIFTH EUROPEAN SYMPOSIUM ON CONTROLLED DRUG DELIVERY, 1 April 1998 (1998-04-01) - 3 April 1998 (1998-04-03), NOORDWIJK AAN ZEE, NETHERLANDS *
STRATMANN ASTRID ET AL: "Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis.", AMERICAN JOURNAL OF PATHOLOGY, vol. 153, no. 5, November 1998 (1998-11-01), pages 1459 - 1466, XP000979137, ISSN: 0002-9440 *
TANAKA S ET AL: "BIOLOGIC SIGNIFICANCE OF ANGIOPOIETIN-2 EXPRESSION IN HUMAN HEPATOCELLULAR CARCINOMA", JOURNAL OF CLINICAL INVESTIGATION,NEW YORK, NY,US, vol. 103, no. 3, 1999, pages 341 - 345, XP000929336, ISSN: 0021-9738 *
THEIS HENRICH ET AL: "Role of VEGF, angiopoietins and their receptors in angiogenesis of renal cell carcinoma.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 10, no. PROGRAM AND ABSTR. ISSUE, September 1999 (1999-09-01), & 32nd Annual Meeting of the American Society of Nephrology; Miami Beach, Florida, USA; November 1-8, 1999, pages 186A, abstract no. A0951, XP000979139, ISSN: 1046-6673 *
WONG M P ET AL: "Down-regulated angiopoietin-1/tie-2 receptor pathway and enhanced expression of vascular endothelial growth factor and angiopoietin-2 in non-small cell lung carcinomas.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), & 90th Annual Meeting of the American Association for Cancer Research; Philadelphia, Pennsylvania, USA; April 10-14, 1999, pages 556, abstract no. 3666, XP002158781, ISSN: 0197-016X *
YOSHIDA YUKIKO ET AL: "Expression of angiostatic factors in colorectal cancer.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 15, no. 6, December 1999 (1999-12-01), pages 1221 - 1225, XP000979115, ISSN: 1019-6439 *
ZAGZAG DAVID ET AL: "In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis.", EXPERIMENTAL NEUROLOGY, vol. 159, no. 2, October 1999 (1999-10-01), pages 391 - 400, XP000979183, ISSN: 0014-4886 *

Also Published As

Publication number Publication date
AU5472200A (en) 2001-01-09
JP2003502391A (en) 2003-01-21
HK1043314A1 (en) 2002-09-13
IL147097A0 (en) 2002-08-14
CA2377188A1 (en) 2000-12-28
EP1185307A2 (en) 2002-03-13
WO2000078361A2 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
WO1999041402A3 (en) Targeting of genetic vaccine vectors
WO1998022136A3 (en) Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies
WO2002058538A3 (en) Methods of imaging and targeting vasculature
AU1875495A (en) 5-substituted derivatives of mycophenolic acid
WO2002087510A3 (en) Subcellular targeting of therapeutic proteins
AU5994100A (en) Multi-pass optical amplifier
AU7357098A (en) Rapid production of autologous tumor vaccines by using hsv amplicon vectors
AU2002350235A1 (en) Combination bacteriolytic therapy for the treatment of tumors
AUPQ071299A0 (en) Vitamin directed dual targeting therapy
AU8014400A (en) Tiltable backboard for cardiopulmonary resuscitation
AU2002303181A1 (en) Morpholino imaging and therapy
AU3928300A (en) Genes associated with diseases of the kidney
WO2006031787A3 (en) Low-obscuration image transmitting particulate ocular therapeutic formulations
AU4770297A (en) Receptor-mediated gene transfer system for targeting tumor gene therapy
WO2002059368A8 (en) Specific mucin expression as a marker for pancreatic cancer
ZA200109838B (en) Substituted arylmalonic acid dinitriles as intermediates for the preparation of herbicides.
WO2002082044A3 (en) Method of imaging cell death in vivo
WO2000078361A3 (en) Methods of imaging and targeting tumor vasculature
WO2000023088A3 (en) Methods of administering adenoviral vectors
WO1999002704A3 (en) Dual specifically phosphatase and methods of use
WO2002068930A3 (en) Methods and reagents to acquire mri signals and images
SE9803482D0 (en) Ion exchange tumor targeting (IETT)
AU2001272967A1 (en) Imaging and targeting tumors using sickle cells
AU2001271284A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU3282900A (en) Target cell-specific, multivalent proteins (mvp)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 10009620

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2377188

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 504422

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 54722/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000939669

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000939669

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000939669

Country of ref document: EP